Francois Raffi
Expertise in
8
conditions

Francois Raffi

Nantes, FR 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
8
conditions
Nantes, FR 

Overview

Francois Raffi practices practicing medicine in Nantes, France.

Mr. Raffi is highly rated in 8 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Hepatitis, Pneumocystis Jiroveci Pneumonia, Pneumonia, and Pancreas Transplant.

He is actively involved in clinical research, co-authoring 249 peer reviewed articles and participating in 9 clinical trials.

Gender

Male

Locations

Nantes, France
Other Locations
Tours, France
Paris, France
Marseille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Dataids Prospective Observational Cohort on Quality of Care of French HIV Infected Patients
Dataids Prospective Observational Cohort on Quality of Care of French HIV Infected Patients
Enrollment Status: Recruiting
Publish Date: February 20, 2026
HIV Prevention in France : Dat'AIDS Prevention
HIV Prevention in France : Dat'AIDS Prevention
Enrollment Status: Recruiting
Publish Date: January 15, 2026
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: Biktarvy, Symtuza
Study Phase: Phase 3
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') or or Authorisation for Early Access (AAP). A Prospective Cohort.
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') or or Authorisation for Early Access (AAP). A Prospective Cohort.
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Other
A Multi-centre, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
A Multi-centre, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Other, Drug
Study Drugs: Remdesivir, Lopinavir, Ritonavir, Interferon Beta-1A, Hydroxychloroquine, AZD7442
Study Phase: Phase 3
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 2 (2a and 2b) Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia
A Randomized, Double-blind, Placebo-controlled Phase 2 (2a and 2b) Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia
Enrollment Status: Completed
Publish Date: March 25, 2022
Intervention Type: Drug
Study Drug: XAV-19
Study Phase: Phase 2
View 7 Less Clinical Trials

249 Total Publications

False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report.
False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report.
Journal: The Journal of antimicrobial chemotherapy
Published: January 19, 2026

Frequently Asked Questions about Francois Raffi

Is Francois Raffi a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Francois Raffi is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Francois Raffi participate in research or clinical trials?

Yes. Francois Raffi has published 249 articles and abstracts on conditions like HIV/AIDS. You can view a list of Francois Raffi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Raffi's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile